Neuroreceptor mechanisms involved in the action of afobazole

Eksperimental'naya i Klinicheskaya Farmakologiya

Volumn 72, Issue 1, 2009, Pages 3-11

  Seredenin, S B ^a   Voronin, M V ^a  

^a INSTITUTE OF PHARMACOLOGY   (Russian Federation)

Author keywords

Afobazole; Immunofluorescence; MAO A; Melatonin receptors; Radioligand binding; Sigma 1 receptors

Indexed keywords

AFOBAZOLE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; BENZIMIDAZOLE; DRUG METABOLITE; M 11 [2 (2 (3 OXOMORPHOLINE 4 YL)ETHYLTHIO) 5 ETHOXY BENZIMIDAZOLE]; MELATONIN RECEPTOR; SIGMA 1 OPIATE RECEPTOR; UNCLASSIFIED DRUG; 2 ((2 MORPHOLINO)ETHYLTHIO) 5 ETHOXYBENZIMIDAZOLE; 2-((2-MORPHOLINO)ETHYLTHIO)-5-ETHOXYBENZIMIDAZOLE; AMINE OXIDASE (FLAVIN CONTAINING); ANXIOLYTIC AGENT; BENZIMIDAZOLE DERIVATIVE; MELATONIN 1 RECEPTOR; MONOAMINE OXIDASE INHIBITOR; MORPHOLINE DERIVATIVE; SIGMA OPIATE RECEPTOR;

ARTICLE; CELL IMMORTALIZATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENDOPLASMIC RETICULUM; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; RADIOASSAY; TRANQUILIZING ACTIVITY; ANIMAL; BINDING COMPETITION; BRAIN; CELL LINE; CELL MEMBRANE; CRICETULUS; CYTOLOGY; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; HAMSTER; METABOLISM; MITOCHONDRION; MOUSE; NERVE CELL; PROTEIN TRANSPORT; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; ANTI-ANXIETY AGENTS; BENZIMIDAZOLES; BINDING, COMPETITIVE; BRAIN; CELL LINE; CELL MEMBRANE; CRICETINAE; CRICETULUS; ENDOPLASMIC RETICULUM; FLUORESCENT ANTIBODY TECHNIQUE; MICE; MITOCHONDRIA; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; MORPHOLINES; NEURONS; PROTEIN TRANSPORT; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, MELATONIN, MT1; RECEPTORS, MELATONIN; RECEPTORS, SIGMA;

EID: 64349085591     PISSN: 08692092     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Russian source
2. Russian source
3. Russian source
4. Russian source
5. Russian source
6. Russian source
7. C. T. Ajmo, Jr., D. O. Vernon, L. Collier, et al., Current neurovascular research, 3(2), 89 - 98 (2006).
8. E. Aydar, C. P. Palmer, V. A. Klyachko, and M. B. Jackson, Neuron, 34(3), 399-410 (2002).
9. J. E. Bermack and G. Debonnel, Journal of pharmacological sciences, 97(3), 317 - 336 (2005).
10. J. A. Boutin, F. Chatelain-Egger, F. Vella, et al., Chemico-biological interactions, 151(3), 213-228 (2005).
11. C. M. Celli, N. Tran, R. Knox, and A. K. Jaiswal, Biochem Pharmacol., 72(3), 366 - 376 (2006).
12. A. M. Cesura, M. Bos, M. D. Galva, et al., Molecular pharmacology, 37(3), 358 - 366 (1990).
13. S. Chen, K. Wu, and R. Knox, Free radical biology & medicine, 29(3-4), 276-284 (2000).
14. Y. Cheng, W. H. Prusoff, Biochemical pharmacology, 22(23), 3099-3108(1973).
15. T. L. Collier, R. N. Waterhouse, and M. Kassiou, Current pharmaceutical design, 13(1), 51 -72 (2007).
16. M. Da Prada, R. Kettler, H. H. Keller, et al., Journal of neural transmission, 29, 279 - 292 (1990).
17. M. L. Dubocovich, M. A. Rivera-Bermudez, M. J. Gerdin, and M. I. Masana, Front Biosci, 8, d1093 - 1108 (2003).
18. A. Feldstein, H. Hoagland, M. Rivera Oktem, and H. Freeman, Int J Neuropsychiatry, 1(4), 384 - 387 (1965).
19. Y. Fu, L. Buryanovskyy, and Z. Zhang, J. Biol. Chem., 283(35), 23829-23835 (2008).
20. M. E. Ganapathy, P. D. Prasad, W. Huang, et al., The Journal of pharmacology and experimental therapeutics, 289(1), 251 -260(1999).
21. B. Halliwell, Journal of neurochemistry, 97(6), 1634-1658 (2006).
22. M. Hanner, F. F. Moebius, A. Flandorfer, et al., Proceedings of the National Academy of Sciences of the United States of America, 93(15), 8072-8077(1996).
23. T. Hayashi and T. Su, The International Journal of Neuropsyc-hopharmacology, 11(Suppliment 1), 116- 117 (2008).
24. T. Hayashi and T. P. Su, Proceedings of the National Academy of Sciences of the United States of America, 101(41), 14949- 14954 (2004).
25. T. Hayashi and T. P. Su, Life sciences, 77(14), 1612- 1624 (2005).
26. T. Hayashi and T. P. Su, Cell, 131(3), 596 - 610 (2007).
27. J. Licinio, M. L. Wong (eds.), Biology of Depression. From Novel Insights to Therapeutic Strategies, WILEY-VCH, Weinhe- im, (2005).
28. A. K. Jaiswal, Free radical biology & medicine, 29(3 - 4), 254 - 262 (2000).
29. O. Jbilo, H. Vidal, R. Paul, et al., J. Biol. Chem., 272(43), 27107-27115 (1997).
30. C. Katnik, W. R. Guerrero, K. R. Pennypacker, et al., The Journal of pharmacology and experimental therapeutics, 319(3), 1355- 1365 (2006).
31. T. Kobayashi, K. Matsuno, M. Murai, and S. Mita, Neurochemical research, 22(9), 1105- 1109 (1997).
32. C. Kopp, E. Vogel, M. Rettori, et al., Neuropharmacology, 39(10), 1865- 1871 (2000).
33. J. J. Kwiek, T. A. Haystead, and J. Rudolph, Biochemistry, 43(15), 4538-4547 (2004).
34. A. S. Lesage, K. L. De Loore, L. Peeters, and J. E. Leysen, Synapse (New York, N. Y), 20(2), 156- 164 (1995).
35. R. Li, M. A. Bianchet, P. Talalay, and L. M. Amzel, Proc. Natl. Acad. Sci USA, 92(19), 8846 - 8850 (1995).
36. S. Liao, J. T. Dulaney, and H. G. Williams-Ashman, J. Biol. Chem., 237, 2981 - 2987 (1962).
37. B. P. Lockhart, P. Soulard, C. Benicourt, et al., Brain Res, 675(1 -2), 110-120(1995).
38. F. Mailliet, G. Ferry, F. Vella, et al., Biochem. Pharmacol, 71(1 -2), 74-88 (2005).
39. F. Mailliet, G. Ferry, F. Vella, et al., FEBS Lett, 578(1-2), 116- 120 (2004).
40. W. R. Martin, C. G. Eades, J. A. Thompson, et al., The Journal of pharmacology and experimental therapeutics, 197(3), 517-532 (1976).
41. M. Martina, M. E. Turcotte, S. Halman, and R. Bergeron, The Journal of physiology, 578(Pt 1), 143 - 157 (2007).
42. K. Matsuno, K. Matsunaga, T. Senda, and S. Mita, The Journal of pharmacology and experimental therapeutics, 265(2), 851 -859(1993).
43. T. Maurice, V. L. Phan, A. Urani, et al., Japanese journal of pharmacology, 81(2), 125- 155 (1999).
44. A. E. Medvedev, A. A. Kirkel, N. S. Kamyshanskaya, et al, Biochemical pharmacology, 47(2), 303 - 308 (1994).
45. P. J. Mohler, J. Q. Davis, L. H. Davis, et al., J. Biol. Chem., 279(13), 12980-12987 (2004).
46. M. P. Morin-Surun, T. Collin, M. Denavit-Saubie, et al., Proceedings of the National Academy of Sciences of the United States of America, 96(14), 8196-8199 (1999).
47. O. Nosjean, M. Ferro, F. Coge, et al., J. Biol. Chem., 275(40), 31311 -31317 (2000).
48. O. Nosjean, J. P. Nicolas, F. Klupsch, et al., Biochem. Pharmacol, 61(11), 1369- 1379 (2001).
49. D.S.Pickering and L. P. Niles, Eur. J. Pharmacol., 175(1), 71 -77(1990).
50. C. Rogers and S. Lemaire, Canadian journal of physiology and pharmacology, 70(11), 1508 - 1514 (1992).
51. F. J. Roman, B. Martin, and J. L. Junien, European journal of pharmacology, 242(3), 305 - 307 (1993).
52. S. B. Seredenin, Psychopharmacology & Biological Narcology, 1 - 2, 494 - 509 (2003).
53. G. F. Steinfels, G. P. Alberici, S. W. Tam, and L. Cook, Neurop-sychopharmacology, 1(4), 321 -327 (1988).
54. T. P. Su, European journal of pharmacology, 75(1), 81-82 (1981).
55. T. P. Su, The Journal of pharmacology and experimental therapeutics, 223(2), 284 - 290 (1982).
56. T. P. Su, E. D. London, and J. H. Jaffe, Science (New York, N. Y), 240(4849), 219-221 (1988).
57. M. Takebayashi, T. Hayashi, and T. P. Su, The Journal of pharmacology and experimental therapeutics, 303(3), 1227- 1237 (2002).
58. M. Takebayashi, T. Hayashi, and T. P. Su, Synapse (New York, N. Y, 53(2), 90-103 (2004).
59. S. W. Tam, Proceedings of the National Academy of Sciences of the United States of America, 80(21), 6703 - 6707 (1983).
60. K. T. Tchedre and T. Yorio, Investigative ophthalmology & visual science, 49(6), 2577 - 2588 (2008).
61. K. Vagnerova, P. D. Hum, A. Bhardwaj, and J. R. Kirsch, Anesthesia and analgesia, 103(2), 430 - 434 (2006).
62. W. Wang, W. D. Le, T. Pan, et al., J. Gerontol. A Biol. Sci. Med. Sci, 63(2), 127- 134 (2008).
63. Z. M. Weil, A. K. Hotchkiss, M. L. Gatien, et al., Brain Res Bull., 68(6), 425 - 429 (2006).
64. P. A. Witt-Enderby and M. L. Dubocovich, Molecular pharmacology, 50(1), 166 - 174 (1996).
65. K. Wu, R. Knox, X. Z. Sun, et al., Archives of biochemistry and biophysics, 347(2), 221 - 228 (1997).
66. Y. Yagasaki, T. Numakawa, E. Kumamaru, et al., J. Biol. Chem., 281(18), 12941 - 12949 (2006).
67. H. Yamamoto, T. Yamamoto, N. Sagi, et al., J. Neurosci, 15(1 Pt 2), 731 -736(1995).
68. S. Yang, A. Bhardwaj, J. Cheng, et al., Anesthesia and analgesia, 104(5), 1179 - 1184, tables of contents (2007).
69. M. B. Youdim and J. P. Finberg, ModProbl Pharmacopsychiatry, 19,63 - 74 (1983).
70. Q. Zhao, X. L. Yang, W. D. Holtzclaw, and P. Talalay, Proc. Natl Acad Sci USA, 94(5), 1669 - 1674 (1997).